Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 5,632,047 shares, a decline of 10.2% from the November 15th total of 6,268,579 shares. Based on an average daily volume of 710,788 shares, the days-to-cover ratio is presently 7.9 days. Currently, 4.9% of the company’s shares are sold short.

Synthetic Biologics (NYSEAMERICAN:SYN) opened at $0.52 on Friday. Synthetic Biologics has a 12-month low of $0.41 and a 12-month high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10).

A number of research analysts have weighed in on the stock. BidaskClub cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th. Zacks Investment Research cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.92.

TRADEMARK VIOLATION WARNING: “Synthetic Biologics, Inc. (SYN) Short Interest Update” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.